IP Verse

Long - Acting Formulations Of Insulins - EP2571517

The patent EP2571517 was granted to Sanofi on Oct 16, 2024. The application was originally filed on May 18, 2011 under application number EP11720115A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2571517

SANOFI
Application Number
EP11720115A
Filing Date
May 18, 2011
Status
Patent Maintained As Amended
May 17, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEDec 24, 2018WICHMANNADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008013938
INTERNATIONAL-SEARCH-REPORTUS2004048783
INTERNATIONAL-SEARCH-REPORTUS2004235710
INTERNATIONAL-SEARCH-REPORTUS2009175840
INTERNATIONAL-SEARCH-REPORTWO2004064862
INTERNATIONAL-SEARCH-REPORTWO2008013938
OPPOSITIONDE102008053048
OPPOSITIONUS2004048783
OPPOSITIONUS2004235710
OPPOSITIONUS2009175840
OPPOSITIONWO2004064662
OPPOSITIONWO2008013938

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "A single-center, randomized, double-blind, 3-treatment, 3-period, 6-sequence cross-over study to compare the pharmacokinetic and pharmacocodynamics effects of single doses of insulin glargine given as u200 and u500 to lantus in a euglycemic clamp setting in subjects with type 1 diabetes", SANOFI - Summary of clinical trial PDY13928, (20120607), XP055541288-
OPPOSITION- "Lantus@ FDA label - NDA 21-081", Center for drug evaluation and research, (20000420), pages 1 - 29, XP055541294-
OPPOSITION- WERNER U. et al., "Insulin Glargine U-100 Has a Favourable Time-Action Profile Compared to U-40 or NPH Insulin in Healthy, Normoglycaemic Dogs", Poster- Abstract 37th Annual Meeting of Endocrine Society of India, (20070000), XP055541301-
OPPOSITION- "Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients", DIABETIC MEDICINE, (20030000), vol. 20, pages 545 - 551, XP002671079
OPPOSITION- SECNIK BOYE KRISTINA et al., "Patient-reported outcomes in a trial of exenatide and insulin giargine for the treatment of type 2 diabetes", HEALTH AND QUALITY OF LIFE OUTCOMES, vol. 4, no. 1, pages 1 - 8, XP021024604

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents